Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
  Pharmaceutical Technology Europe E-Alert
 
17 August 2012

IN THIS ISSUE
Elan Spin Off
AstraZeneca and BMS
Zoetis IPO
Stem Cell Institute
PhRMA Awards


Elan to Spin Off Discovery Sciences
Elan Corporation has announced plans to spin off its discovery unit and Neotope Biosciences division to create an independent entity focused on R&D. More...
 
AstraZeneca and BMS Extend Diabetes Alliance
AstraZeneca has paid approximately $3.2 billion to extend its diabetes alliance with Bristol-Myers Squibb (BMS), following BMS's recently completed acquisition of Amylin Pharmaceuticals. More...
 
Pfizer's Zoetis Subsidiary Files IPO
Zoetis, a subsidiary of Pfizer, filed a registration statement with the US Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock. More...
 
UK invests in $12.5-million Stem-Cell Institute
The UK is to invest £8 million ($12.5 million) in a new center that will be dedicated to stem-cell biology and medicine, with the aim of developing new therapeutic approaches to illnesses that currently have no effective treatments. More...
 
PhRMA Research Awards Focus on Alzheimer's Disease
In September, PhRMA is cohosting a brand new US awards programme in to honour individuals and organizations who have contributed significantly to the fight against Alzheimer's Disease. More...
 
Join our community on LinkedIn
Want to discuss any of this week's news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More...
Key Topics:

Latest blog posts
PhRMA Defends US Innovation
Three Reasons to Adopt Automated Validation in Quality Management Systems
PhRMA Research Awards Focus on Alzheimer's
More blog posts

Latest articles
Bioavailability Enhancement: When to Use Hot-Melt Extrusion versus Spray Drying
Tackling Solubility Issues with Nanoparticle Engineering
Top Technologies: Biopharmaceutical Equipment
More articles

Upcoming events
2012 PDA FDA Joint Regulatory Conference (10–12 September | US)
World Drug Safety Congress Europe 2012 (11–13 September | UK)
Biological Production Forum (24–26 September | Germany)
More events

Products/Service Profiles
Agilent

Realize Effective Pharmaceuticals
Reliable solutions enable pharmaceutical scientists to innovate in disease research, accelerate drug discovery and have greater confidence throughout development and manufacturing. Agilent solutions in genomics research, automation, separation and detection technologies along with workflow driven software solutions helps deliver the answers to bring effective therapeutics to market.
Learn about pharmaceutical purification, purity, and impurity analyses at www.agilent.com/lifesciences/realizepharma

 
Agilent

Advances in Label-Free Technology (Video) – Click to Watch
Watch this customer success story as told by GSK in this video. Learn how you too can unlock challenging targets, simplify assay design, and shorten time to results with the Agilent RapidFire System. In this video, GSK presents the findings from their studies using the RapidFire High-throughput Mass Spectrometry System in various stages of the lead discovery process.
Re-Imagine Mass Spectrometry Throughput Watch the video

 
Pharmaceutical Press

Handbook of Pharmaceutical Excipients, NEW 7th edition. Special offer price - available now.
A new edition of the Handbook has always seen important developments, and this edition is no exception. Not only has the entire volume been reviewed and updated, significant new content has been added.
Read more


Event Profile

Pharma Integrates 2012
Nov 28-29 2012
London, UK
Where do you see partnerships strategically?
This is the central question that Pharma Integrates 2012 (PI2012) will tackle. PI2012 is the exclusive retreat for the bio/pharmaceutical procurement and outsourcing elite.
Read more

Survey
Into which pharmerging market — aside from China and India — is your company most interested in expanding manufacturing operations?
 
Brazil 36%
 
 
Turkey 11%
     
 
Russia 15%
     
 
Indonesia 7%
     
 
Argentina 6%
     
 
South Africa 5%
     
 
Other 20%

This week we would like to know...

Do you think large drug settlements to settle criminal and civil liabilities are an appropriate deterrent to corporate malpractices such as unlawful promotion of drugs and failure to report safety data?

Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.